J&J scraps late-stage RSV vaccine in R&D
overhaul, dropping out of race with GSK, Pfizer
Johnson & Johnson is 'exiting' a late-stage respiratory syncytial virus program amid a large-scale overhaul of its infectious disease unit.
Johnson & Johnson is 'exiting' a late-stage respiratory syncytial virus program amid a large-scale overhaul of its infectious disease unit.
No comments:
Post a Comment